866-997-4948(US-Canada Toll Free)

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 66 Pages


Global Markets Directs, \'Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL). 

Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Relapsed Chronic Lymphocytic Leukemia (CLL).
  • A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) 8
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies 10
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Development by Companies 15
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Development 17
Boehringer Ingelheim GmbH 17
Emergent BioSolutions Inc. 18
Santaris Pharma A/S 19
Pharmacyclics, Inc. 20
Memgen, LLC. 21
NOXXON Pharma AG 22
SBI Biotech Co., Ltd. 23
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
navitoclax - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ibrutinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SPC-2996 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TRU-016 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ISF-35 + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 41
GNKG-168 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
navitoclax + [cyclophosphamide] + [fludarabine] + [rituximab] - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TRU-016 + [bendamustine hydrochloride] - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BI-836826 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ABT-199 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Bendamustine + Ofatumumab + Methylprednisolone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
NOX-A-12 + Bendamustine + Rituximab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Lenalidomide + Alemtuzumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Bendamustine + [Alemtuzumab] - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates 55
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 62
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 63
Featured News & Press Releases 63
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom\'s Macroglobulinemia 63
Aug 01, 2012: Pharmacyclics To Receive $50m Milestone Payment From Janssen Biotech 63
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib Combination Study At European Hematology Association Annual Congress 64

Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Table


Number of Products Under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2013 8
Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Boehringer Ingelheim GmbH, H1 2013 17
Emergent BioSolutions Inc., H1 2013 18
Santaris Pharma A/S, H1 2013 19
Pharmacyclics, Inc., H1 2013 20
Memgen, LLC., H1 2013 21
NOXXON Pharma AG, H1 2013 22
SBI Biotech Co., Ltd., H1 2013 23
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates 55
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 62

List of Chart


Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2013 8
Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *